Recent clinical data on experimental cancer treatments points to strong future product sales, according to an emailed report from Moody's Investors Service.
To compile the report, Moody's analyzed data drug companies presented at the American Society of Clinical Oncology meeting held June 3 to June 7 in Chicago.
Here are four report findings.
- Moody's predicts breast cancer and lung cancer will be the largest drivers of sales growth in 2017 and 2018.
- Merck, AstraZeneca, Eli Lilly and Incyte Corp., will benefit the most from this growth, according to the report.
- Roche, Pfizer and Bristol-Myers Squibb will experience increasing competitive pressures in the future cancer drug market. However, these drugmakers will still benefit from ongoing development of new oncology treatments.
- Combination regimens will grow into increasingly important drug therapies.
More articles on supply chain:
Across enemy lines: Insurer recruits former drug reps to push more generics
Joslin Diabetes Center affiliate HSHS Medical Group to offer MiniMed insulin pump
FDA OKs Claret Medical's stroke prevention device